Receive monthly emails about the latest oncology research and technology, new patient services, resources and more!

Please select an option below to help us tailor your newsletter to best suit your content interests!

No thanks
BILIARY TRACT: METASTATIC: 1st Line: SWOG S1815

A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

Title
SWOG S1815 (Biliary Tract)
Study Title

A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

Site Link
Malignancy
Biliary Tract, cholangiocarcinoma, gallbladder cancer, bile duct cancer
Stage
Disease Setting
Metastatic/Palliative
Line Of Therapy
1st Line
Investigational Agent
nab-paclitaxel
Drug Class
taxane
PI
Axel Grothey, MD
Sponsor
Southwest Oncology Group (SWOG)
Phase
Status
Key Eligibility Criteria
Key Eligibility Criteria Details
  • Histologically confirmed intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, or gallbladder cancer
  • Must have metastatic or unresectable disease and no prior therapy for metastatic disease
  • Does not need to be measurable disease
  • No ampullary cancer
  • No adjuvant therapy within 6 months prior to registration
  • ECOG PS 0-1
  • No other prior malignancy within 2 years
Objective
  • Primary
    • OS
  • Secondary
    • PFS
    • ORR
    • DCR
    • Safety
    • CA19-9 levels
Assessment Frequency
_
Assessment Frequency 2
_



Assessment Frequency Link
Path
biliary carcinoma
Dosing Frequency
Control Agents
Study Protocol
Randomized
Yes
X